BL
ALNY icon

BFSG LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

BFSG LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1K Hold
50
– – ﹤0.01% 541
2026
Q1 		$16.5K Buy
+50
New +$17K ﹤0.01% 520

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
PSC
Portman Square Capital London, United Kingdom $2.11B AUM 19.71% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM

BFSG LLC's ALNY Position: Q2 2026 in Review

BFSG LLC held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 50 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #541.

BFSG LLC first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $16.5K in Q1 2026. 104 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • BFSG LLC held 50 shares of Alnylam Pharmaceuticals worth $15.1K as of Q2 2026.
  • BFSG LLC left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of BFSG LLC's portfolio in Q2 2026, its #541 holding.
  • BFSG LLC first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • BFSG LLC's Alnylam Pharmaceuticals position peaked at $16.5K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on BFSG LLC's 13F filing for Q2 2026, filed 20 Jul 2026.